MedTrace Logo

Study of the Role of Genetic Modifiers in Hemoglobinopathies

NCT05799118 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30000

Last updated 2024-03-20

No results posted yet for this study

Summary

This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).

Conditions

Interventions

GENETIC

GWAS

The study will perform a GWAS experiments for all recruited subjects. The blood sample will be collected during routine clinical visits, only if DNA is not already available in existing biobanks. All individuals will provide consent for participation in the study.

Sponsors & Collaborators

  • Cyprus Institute of Neurology and Genetics

    lead OTHER

Principal Investigators

  • Petros Kountouris, PhD · Cyprus Institute of Neurology and Genetics

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • United States
  • Angola
  • Argentina
  • Belgium
  • Brunei
  • Cyprus
  • Democratic Republic of the Congo
  • Denmark
  • Greece
  • Israel
  • Italy
  • Malaysia
  • Nigeria
  • Pakistan
  • Portugal
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05799118 on ClinicalTrials.gov